4-0-Substituted -2-deoxystreptamine aminoglycoside derivatives, their preparation and formulations containing them.

摘要

Novel compounds are disclosed which are 2 min -N-acylated or 2 min -N-alkylated derivatives of a 4-O-substituted-2-deoxystreptamine aminoglycoside selected from the group consisting of: apramycin, alpha or beta -(C1 to C6 alkyl)aprosaminide, alpha or beta -(C2 to C6 hydroxyalkyl)aprosaminide, alpha or beta -(C2 to C6 aminoalkyl)aprosaminide, alpha or beta -(C2 to C6 protected aminoalkyl)aprosaminide, alpha or beta -(C3 to C6 aminohydroxyalkyl)aprosaminide, alpha or beta -(C3 to C6 (protected amino)hydroxyalkyl)aprosaminide, or a pharmaceutically-acceptable acid addition salt thereof; wherein the acyl or alkyl substituent group is selected from the group consisting of gamma -amino- alpha -hydroxybutyryl, gamma -protected amino- alpha -hydroxybutyryl, beta -amino- alpha -hydroxypropionyl, beta -protected amino- alpha -hydroxypropionyl, glycyl, N-protected glycyl, 3-hydroxypyrrolidine-3-carbonyl, N-protected 3-hydroxypyrrolidine-3-carbonyl, 3-hydroxyazetidine-3-carbonyl, N-protected 3-hydroxyazetidine-3-carbonyl, 2-hydroxy-2-(azetidin-3-yl)acetyl, N-protected 2-hydroxy-2-(azetidin-3-yl)acetyl, 4-amino-2-hydroxybulyl, 3-amino-2-hydroxypropyl, 2-aminoethyl, 3-hydroxypyrrolidine-3-methylene, 3-hydroxyazetidine-3-methylene, 2-hydroxy-2-(azetidin-3-yl)ethyl, C2 to C4 alkyl, C3 to C5 allyl, benzyl and substituted benzyl. They are useful for treating warm blooded animals suffering from bacterial diseases. They and 2 min -N-acylated and 2 min -N-alkylated derivatives of lividamine, paromamine and the 6 min -N-protected derivatives of nebramine, neamine, gentamine C1, gentamine C1a, gentamine C2, gentamine C2a, and gentamine C2b, and pharmaceutically-acceptable acid addition salts thereof can be prepared by reacting the corresponding aminoglycoside substrate with a nickel salt Ni (X2), X being C1 to C10 carboxylate, in water, diluting with a polar organic solvent, treating with an alkylating agent or acylating agent, optionally, deprotecting the amino or N-protected substituents, optionally, reducing carbonyl portions of an acyl group, and recovering as a free base or as a pharmaceutically-acceptable acid addition salt.